Cannabinoid receptor 2 agonist AM1241 inhibits fibrous scarring after spinal cord injury in rats

Cannabinoid receptor 2 agonist AM1241 inhibits fibrous scarring after spinal cord injury in rats

Objective To determine the role of cannabinoid receptor 2 (CBR2) agonist, AM1241, in the formation of fibrous scars in rats after spinal cord injury and elucidate the underlying mechanism. Methods A total of 144 female Sprague-Dawley rats were selected and divided into 4 groups: sham operation grou...

Full description

Bibliographic Details
Main Authors:	LING Chengming, CHU Weihua1, YUAN Jichao, CHEN Xin, LIU Jingjing
Format:	Article
Language:	zho
Published:	Editorial Office of Journal of Third Military Medical University 2022-05-01
Series:	Di-san junyi daxue xuebao
Subjects:	cannabinoid receptor 2 cannabinoid receptor 2 agonist spinal cord injury fibrous scar macrophage polarization
Online Access:	http://aammt.tmmu.edu.cn/Upload/rhtml/202202141.htm

Similar Items

Evaluating signaling bias for synthetic cannabinoid receptor agonists at the cannabinoid CB2 receptor
by: Monica Patel, et al.
Published: (2023-12-01)

Cannabinoid Receptor 1 Agonist ACEA and Cannabinoid Receptor 2 Agonist GW833972A Attenuates Cell-Mediated Immunity by Different Biological Mechanisms
by: Nuchjira Takheaw, et al.
Published: (2023-03-01)

Differential activation of G protein‐mediated signaling by synthetic cannabinoid receptor agonists
by: Shivani Sachdev, et al.
Published: (2020-04-01)

Cannabinoid Receptor Agonist Inhibits Atrial Electrical Remodeling in a Tachypaced Ex Vivo Rat Model
by: Danielle I. Lee, et al.
Published: (2021-04-01)

Pharmacological Properties, Therapeutic Potential and Molecular Mechanisms of JWH133, a CB2 Receptor-Selective Agonist
by: Hebaallah Mamdouh Hashiesh, et al.
Published: (2021-07-01)

Synthesis and pharmacological evaluation of newly detected synthetic cannabinoid receptor agonists AB-4CN-BUTICA, MMB-4CN-BUTINACA, MDMB-4F-BUTICA, MDMB-4F-BUTINACA and their analogs
by: Eric Sparkes, et al.
Published: (2022-09-01)

Synthesis and In Vitro Characterization of Selective Cannabinoid CB2 Receptor Agonists: Biological Evaluation against Neuroblastoma Cancer Cells
by: Francesca Gado, et al.
Published: (2022-05-01)

Cannabinoid CB1 and CB2 Receptor-Mediated Arrestin Translocation: Species, Subtype, and Agonist-Dependence
by: Mikkel Søes Ibsen, et al.
Published: (2019-04-01)

The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients
by: Melissa A. Jackson, et al.
Published: (2021-07-01)

Cannabinoid receptor agonist attenuates angiotensin II–induced enlargement and mitochondrial dysfunction in rat atrial cardiomyocytes
by: Danielle I. Altieri, et al.
Published: (2023-04-01)

The use of cannabinoids in epilepsy as an example: medical, social, and legal aspects
by: R. G. Akzhigitov, et al.
Published: (2020-08-01)

Selective Cannabinoid 2 Receptor Agonists as Potential Therapeutic Drugs for the Treatment of Endotoxin-Induced Uveitis
by: Richard Frederick Porter, et al.
Published: (2019-09-01)

Cannabinoid receptors distribution in mouse cortical plasma membrane compartments
by: Hajar Miranzadeh Mahabadi, et al.
Published: (2021-06-01)

Cannabinoid CB2 receptor ligands disrupt the sequential regulation of p-MEK1/2 to p-ERK1/2 in mouse brain cortex
by: Glòria Salort, et al.
Published: (2023-10-01)

Impact of the mouse estrus cycle on cannabinoid receptor agonist‐induced molecular and behavioral outcomes
by: Hye Ji J. Kim, et al.
Published: (2022-06-01)

Characterization of Subtype Selective Cannabinoid CB<sub>2</sub> Receptor Agonists as Potential Anti-Inflammatory Agents
by: Yaliang Tang, et al.
Published: (2021-04-01)

Cannabinoid receptors type 2: Function and development in agonist discovery from synthetic and natural sources with applications for the therapy of osteoporosis
by: Si-jing Hu, et al.
Published: (2024-02-01)

Hydrogen Sulfide Interacting with Cannabinoid 2 Receptors during Sciatic Nerve Injury-Induced Neuropathic Pain
by: Xue Bai, et al.
Published: (2023-05-01)

Enantiospecific Synthesis, Chiral Separation, and Biological Activity of Four Indazole-3-Carboxamide-Type Synthetic Cannabinoid Receptor Agonists and Their Detection in Seized Drug Samples
by: Lysbeth H. Antonides, et al.
Published: (2019-05-01)

Therapeutic Potential of Cannabinoids in Glaucoma – Hit or Myth? - A Review
by: Julia Górny, et al.
Published: (2024-11-01)

Activity-based detection of synthetic cannabinoid receptor agonists in plant materials
by: Axelle Timmerman, et al.
Published: (2024-07-01)

Cannabinoids and Neurogenesis: The Promised Solution for Neurodegeneration?
by: Andrea Valeri, et al.
Published: (2021-10-01)

In Vitro Metabolic Fate of the Synthetic Cannabinoid Receptor Agonists QMPSB and QMPCB (SGT-11) Including Isozyme Mapping and Esterase Activity
by: Matthias J. Richter, et al.
Published: (2021-08-01)

New Insights Into Peptide Cannabinoids: Structure, Biosynthesis and Signaling
by: Agustín Riquelme-Sandoval, et al.
Published: (2020-12-01)

Brain Cannabinoid Systems as Targets for the Therapy of Neurological Disorders
by: Paul Consroe
Published: (1998-12-01)

The effect of cannabinoid type 2 receptor agonist on morphine tolerance
by: Di Cui, et al.
Published: (2024-06-01)

Cannabinoid CB1 Receptor Involvement in the Actions of CBD on Anxiety and Coping Behaviors in Mice
by: Amaya Austrich-Olivares, et al.
Published: (2022-04-01)

Cannabinoid type-2 receptors: An emerging target for regulating schizophrenia-relevant brain circuits
by: Anthony S. Ferranti, et al.
Published: (2022-08-01)

Astroglial CB1 Cannabinoid Receptors Mediate CP 55,940-Induced Conditioned Place Aversion Through Cyclooxygenase-2 Signaling in Mice
by: Jin Cong, et al.
Published: (2021-11-01)

2-Arylpropionic Acid Pyrazolamides as Cannabinoid CB2 Receptor Inverse Agonists Endowed with Anti-Inflammatory Properties
by: Daniela R. de Oliveira, et al.
Published: (2022-12-01)

Reference gene validation for the relative quantification of cannabinoid receptor expression in human odontoblasts via quantitative polymerase chain reaction
by: Laura M. Navarro-Saiz, et al.
Published: (2022-11-01)

The Impact of the CB<sub>2</sub> Cannabinoid Receptor in Inflammatory Diseases: An Update
by: Volatiana Rakotoarivelo, et al.
Published: (2024-07-01)

Cannabinoids: New Promising Agents in the Treatment of Neurological Diseases
by: Sabrina Giacoppo, et al.
Published: (2014-11-01)

Structure-Based Virtual Screening and Molecular Dynamics Simulation Assessments of Depsidones as Possible Selective Cannabinoid Receptor Type 2 Agonists
by: Gamal A. Mohamed, et al.
Published: (2023-02-01)

The Vertical and Horizontal Pathways in the Monkey Retina Are Modulated by Typical and Atypical Cannabinoid Receptors
by: Joseph Bouskila, et al.
Published: (2021-11-01)

Therapeutic Potential of Cannabinoids in Glaucoma
by: Theresa Lindner, et al.
Published: (2023-08-01)

Cannabinoid 2 Receptor Agonist Improves Systemic Sensitivity to Insulin in High-Fat Diet/Streptozotocin-Induced Diabetic Mice
by: Xiuyuan Zhang, et al.
Published: (2016-12-01)

Activation of Cannabinoid Receptor Type II by AM1241 Ameliorates Myocardial Fibrosis via Nrf2-Mediated Inhibition of TGF-β1/Smad3 Pathway in Myocardial Infarction Mice
by: Xiang Li, et al.
Published: (2016-09-01)

Structure–Activity Relationship Development Efforts towards Peripherally Selective Analogs of the Cannabinoid Receptor Partial Agonist BAY 59-3074
by: George Amato, et al.
Published: (2022-09-01)

Brodifacoum does not modulate human cannabinoid receptor-mediated hyperpolarization of AtT20 cells or inhibition of adenylyl cyclase in HEK 293 cells
by: Shivani Sachdev, et al.
Published: (2019-09-01)